Immunization with different formulations of *Mycobacterium tuberculosis* antigen 85A induces immune responses with different specificity and protective efficacy

Elma Tchilian a,∗, Diksha Ahuja a, Ariann Hey a, Shisong Jiang b, Peter Beverley a

a University of Oxford, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK
b University of Oxford, Department of Oncology, Old Road Campus Research Building, Roosevelt Drive, Oxford OX3 7DQ, UK

**ABSTRACT**

To test the relative efficacy of CD4 and CD8 T cells in mediating protective immunity to *Mycobacterium tuberculosis* (Mtbc), we compared three immunization regimes designed to induce preferentially each subset. BALB/c mice were immunized intranasally (i.n.) or parenterally with antigen 85A either in a recombinant Adenoviral vector (Ad85A), as recombinant protein (r85A) or as a set of overlapping 15mer peptides (p85A). For the first time we show that i.n. immunization with overlapping 85A synthetic peptides as well as Ad85A or r85A can provide protection against Mtbc challenge. For all forms of the antigen, i.n. induces greater protection against Mtbc challenge than parenteral immunization. Ad85A induces a predominantly CD8 T cell response against the 85A10-28 epitope, r85A a CD4 response to 85A99-118 and p85A a balanced CD4/CD8 response to the CDR 85A10-28 and 85A99-118 epitopes. Immune responses to CD4 85A145-152 and CD8 85A10-28 but not CD8 85A145-152 are protective. Although Ad85A induces a strong response to the protective CD8 85A10-28 epitope, we could not induce any response to this epitope by peptide immunization. These results show that although peptide immunization can induce protective immunity to Mtbc challenge, it can also induce a response to a non-protective epitope in antigen 85A, indicating that the specificity of an immune response may be more important for protection against Mtbc than its magnitude. These findings have important implications for the application of such vaccines in humans.

© 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY license.

1. Introduction

Tuberculosis (TB) remains an important disease worldwide and new vaccines to replace or boost the protection afforded by the existing vaccine, Bacille Calmette Guérin (BCG), are much needed, especially in view of the development and spread of multidrug resistant strains of *Mtb*. Members of the mycolyl transferase family of *Mtb* proteins, also called the antigen 85 complex, are amongst the most prominent tuberculosis vaccine candidates [1] because immune responses to these antigens can be detected in the majority of humans exposed to *Mtb* [2]. Numerous studies have shown that immunization with antigen 85 complex proteins, using a variety of vaccine platforms, can provide protection against Mtbc challenge in animal models [1,3–6].

We have used antigen 85A as a model vaccine antigen to explore in mice how to induce protection against Mtbc challenge and define the features and mode of action of protective immune responses. These experiments have shown that intranasal (i.n.) immunization is a highly effective route of administration [6,7] inducing an activated population of lung resident T cells that inhibit mycobacterial growth very early after Mtbc challenge, in contrast to the later effect of parenteral immunization [6,8–11]. Furthermore, under some circumstances mucosal and parenteral immunization can have additive protective effects [6,10].

Although recent studies are beginning to define the characteristics of protective pulmonary mucosal immune responses [12] and need for pathogen associated molecular pattern signals for appropriate innate immune system activation [13,14], many questions remain to be resolved, particularly the relative importance of CD4 and CD8 T cells in protection against early mycobacterial growth established by pulmonary immunization. In this study we compare the protective efficacy of immunization protocols designed...
to induce CD4 or CD8 biased or balanced CD4/8T cell responses to the single Mtb antigen, 85A. We show that the CD4 response to 85A is protective but that CD8T cell responses may be protective or non-protective, depending on their epitope specificity.

2. Materials and methods

2.1. Mice and immunization

All experiments were performed with 6–8 week old female BALB/c mice (Harlan Orlac, Blackthorn, UK), were approved by the animal use ethical committee of Oxford University and complied with UK Home Office guidelines. Mice were immunized as shown in Fig. 1, with either recombinant human serotype 5 adenovirus expressing 85A (Ad85A) [9], recombinant 85A protein (r85A) or with 15mer peptides overlapping by 10 amino acids covering the entire protein sequence of 85A (p85A) (Suppl. Table 1).

Supplementary data associated with this article can be found, in the online version, at http://dx.doi.org/10.1016/j.vaccine.2013.07.040.

2.1.1. Ad85A

Mice were immunized once with Ad85A. For i.n. immunization, mice were anaesthetized with isoflurane/oxygen and 2 × 10^9 virus particles (vp) of Ad85A containing 40 µl of PBS was administered with a pipette divided between both nostrils. For intramuscular (i.m.) immunization 2 × 10^9 vp of Ad85A was administered in the hind legs in a total volume of 50 µl.

2.1.2. r85A

Mice were immunized three times at 2 week intervals with 2 µg of r85A protein (a kind gift from KLMC Franken and THM Ottenhoff) prepared as described previously [10,15]. For i.n. immunization mice were anaesthetized with isoflurane/oxygen and 2 µg of r85A was mixed with 2 µg of cholera toxin (CT) (Sigma, UK) and pipetted into the nostrils in a total volume of 40 µl. Mice were also immunized subcutaneously (s.c.) with 2 µg of r85A in 200 µl of monophosphoryl lipid A (MPL) (Sigma, UK).

2.1.3. p85A

Mice were immunized three times at 2 week intervals with 500 ng of each of the sixty-six 15mer peptides overlapping by 10 amino acids covering the entire sequence of antigen 85A (p85A) as described for r85A. For immunization against CD8 85A99–118 1 µg of each of the four peptides covering the region containing the 99–118 epitope, TFLTSELPGWLQAN, SELPGWLNQRHVKP, WIIQANRHVKPTGS, and RHVKPTGSAVGLSM (peptides 29, 30, 31 and 32 in Suppl. Table 1), were administered with adjuvant i.n. or s.c. as above.

For immunization against CD8 85A90–78 1 µg of each of the three peptides covering the region containing the 78–90 epitope QSLGSLVMPVGQSS, VVMPVGQSSFPYSDW, GGQSSFPYSDWYQWAC (peptides 22, 23 and 24 in Suppl. Table 1) were administered with adjuvant i.n. or i.m. as above.

For immunization against CD8 85A145–152 1 µg each of the two peptides covering the region containing the 145–152 epitope, YHPQPQFVYAGAMSGL and FVYAGAMSGLLPDSQ (peptides 37 and 38 in Suppl. Table 1) were administered with adjuvant i.n. or s.c. as above.

Mice were also immunized either with all peptides except the CD4 85A90–118 region (all peptides except peptides 29, 30, 31 and 32), all peptides except the CD8 85A78–90 region (lacking peptides 22, 23 and 24) or without the CD8 85A145–152 region (lacking peptides 37 and 38) or in combinations as in the text.

2.2. Isolation of lymphocytes from lungs and spleen

Lungs were perfused with PBS, cut into pieces and digested with 0.7 mg/ml collagenase type I (Sigma) and 30 µg/ml DNase I (Sigma) for 45 min at 37 °C. Digested fragments were crushed through a cell strainer using a syringe plunger, washed, layered over Lympholyte (Cederlane, Ontario, Canada) and centrifuged at 1000 × g for 25 min. Interface cells were collected and washed. Spleens were passed through a cell strainer using a syringe plunger, red blood cells were removed with lysis buffer (Qiagen, Crawley, UK) and the cells were washed.

2.3. Flow cytometry

Cells were cultured in Hepes buffered RPMI, 10% heat-inactivated FCS, L-glutamine, penicillin and streptomycin for 6 h. Cells from Ad85A immunized animals were stimulated for 6 h with either sixty-six 15mer peptides overlapping by 10 amino acids covering the 85A protein sequence or with pool of peptides containing about 10 consecutive peptides or with 3 peptides (Peptide Protein Research Ltd., Fareham, UK) encoding the dominant CD4 (Ag85A99–118aa TFLTSELPGWLQANRHVKP) and CD8 (Ag85A70–78aa MPVGGQSSF and Ag85A145–152aa YAGAMSGL) peptide epitopes [9] (Peptide Protein Research Ltd). Each peptide was at 2 µg/ml. After 2 h at 37 °C, Golgi Plug (BD Biosciences, Oxford, UK) was added according to the manufacturer’s instructions.

Cells were washed and incubated with CD16/CD32 monoclonal antibody to block FC binding. Subsequently the cells were stained for CD4 (RM4-5), CD8 (53–67) (BD Bioscience, Oxford, UK), IFNγ (XMG1.2) (eBioscience, Hatfield, UK) using the BD Cytofix/Cytokerit according to the manufacturer’s instructions.

Cells were run on a LSRII (BD Biosciences) and analyzed using Flowjo software (Tree Star Inc., Ashland, Oregon, USA). For simplicity IFNγ intracellular staining was used to detect the majority of antigen specific CD4 and CD8T cells, since the experiments were concerned with the specificity of the response to 85A and not its quality.

2.4. Infection with Mtb and determination of mycobacterial load

Five to 7 mice were anesthetized with isoflurane/oxygen and infected i.n. with Mtb (Erdsman strain) in 40 µl PBS. Lung CFU were enumerated 24 h after challenge to determine the number of organisms deposited (~200 CFU). Mice were sacrificed at indicated times, the lungs and spleen homogenized and mycobacterial load determined by plating 10-fold serial dilutions of tissue homogenates on Middlebrook 7H11 agar plates (E&O Laboratories Ltd., Bonnybridge, UK). Colonies were counted after 3–4 weeks of incubation at 37 °C in 5% CO2.

2.5. Statistical analysis

Data were analyzed using one-way ANOVA followed by Tukey’s multiple comparison test.

3. Results

3.1. Immunization with 85A in three different vaccine platforms is more protective intranasally than parenterally

We first examined protection against Mtb challenge afforded by antigen 85A administered either as Ad85A, r85A or p85A (Fig. 1).

Mice immunized with Ad85A i.n. or i.m., were challenged after 5 weeks and Mtb lung CFU assessed 4 weeks later. The lung mycobacterial load is reduced by ~0.6 log10 in Ad85A i.m. immunized compared to naive animals, while Ad85A i.n. mice show
Experimental design

![Experimental design diagram]

Fig. 1. Experimental design. Horizontal lines indicate the time scale of the experiments and the vertical bars show immunizations, Mtb challenge and harvest for CFU assay.

an \(~1.3 \log_{10}\) reduction (Fig. 2A). This is consistent with previous observations showing superior protection of i.n. administered Ad85A compared to parenteral routes [6,7].

To determine the protection afforded by r85A, BALB/c mice were immunized with r85A either i.n. or s.c. as shown in Fig. 1 and challenged five weeks after the last immunization. Intranasal immunization with r85A decreases the mycobacterial load by \(~1.5 \log_{10}\) compared to naive mice, while parenteral immunization has an insignificant effect (Fig. 2B). Similar results are obtained when the mice are immunized with p85A. The i.n. immunized animals show a significantly reduced Mtb load while s.c. immunization has an insignificant effect (Fig. 2C). We also immunized mice 3 times with CT i.n. or MPL s.c. and challenged them with Mtb. The mycobacterial burden in these controls does not differ from that found in naive animals (data not shown).

Taken together these data show that the i.n. route of administration of Ad85A, rec85A or p85A, is more effective against Mtb challenge than parenteral immunization in BALB/c mice when CT and MPL are used as the mucosal and parenteral adjuvants.

### 3.2. Specificity of the immune responses to 85A administered in different vaccine platforms

The same antigen was administered in all immunization platforms and the outcome in terms of protection was similar in all i.n. immunized mice. However, since Ad85A induces a predominantly CD8 T cell [6,9,11] while recombinant proteins in adjuvant induce CD4 T cell responses [5,16,17] and 15mer peptides might induce both CD4 and 8 responses [18], we investigated the specificity of the immune responses to Ad85A, r85A and p85A.

Peptide pools covering the whole sequence of antigen 85A protein were used to stimulate lung and spleen cells from immunized mice for 6 h in vitro and intracellular staining for IFN\(\gamma\) was performed to detect the majority of antigen specific CD4 and CD8 T cells (data not shown). After identifying the response to a pool, the exact sequence of the peptide was narrowed down using individual 15mer peptides overlapping by 10 amino acids. We identified three major immunodominant epitopes: CD4 85A\(_{99-118}\), CD8 85A\(_{70-78}\) and CD8 85A\(_{145-152}\) as previously shown for antigen 85A in H-2\(^b\) mice [19]. However the different vehicles induce very different responses.

After Ad85A immunization most of the CD8 responding cells in the lungs and spleen react to the dominant 85A\(_{70-78}\) epitope and a smaller proportion to the 85A\(_{145-152}\) epitope. As previously shown there is also a small but detectable CD4 response to the 85A\(_{99-118}\) epitope. While the administration of Ad85A i.n. induces marginally stronger lung responses, the i.m. route induces stronger splenic CD8 85A\(_{145-152}\) and CD4 responses (Fig. 3A). In all figures, for simplicity we present only IFN\(\gamma\) data for CD4 and CD8 cells. When we used staining for TNF slightly fewer antigens specific were detected but the relative magnitude of responses to different epitopes was unchanged, while IL-2 stained few CD8T cells but could be used to detect CD4 antigen specific cells, giving similar results to IFN\(\gamma\) for this subset (data not shown).

Administration of r85A i.n. induces an \(~5\%\) lung CD4 response against 85A\(_{99-118}\) but hardly detectable CD8 responses and this route induces larger responses not only in the lung but also in the spleen (0.4%) compared to s.c. immunization (0.1%) (Fig. 3B). Minimal and inconsistent CD4 responses are also detected against the 85A\(_{141-156}\) (FYVAGAMSGLDPSQ peptide 38), 85A\(_{178-193}\) (DMWGPKEDPAWQRND peptide 45) or 85A\(_{205-214}\) (GKLJANNTRVVWVCYG peptide 49) epitopes (data not shown), in accordance with previous studies in BALB/c mice (Suppl. Table 1) [19].

Animals immunized i.n. with p85A generate strong lung responses against the CD4 85A\(_{99-118}\) (~23%) and CD8 85A\(_{145-152}\) (~23%). Surprisingly no response to the CD8 85A\(_{70-78}\) epitope is detected. As with the other two regimes, i.n. immunization induces a stronger lung response compared to the parenteral route. Furthermore p85A i.n. induces a larger splenic response (~1% CD4 and 0.3%
3.3. Protective efficacy of CD4 85A99–118 and epitopes CD8 85A145–152 against Mtb challenge

Since p85A i.n. induces both strong CD4 85A99–118 and CD8 85A145–152 specific responses we wished to determine the contribution of each of these epitope to protection against Mtb. We therefore immunized mice with peptides covering the CD4 85A99–118 or CD8 85A145–152 regions. In both cases the expected immune responses, to CD4 85A99–118 or CD8 85A145–152 are induced (Fig. 4A and B). The mice responding only to the CD4 85A99–118 epitope are protected as well as those immunized with all peptides, but strikingly, animals responding only to CD8 85A145–152 are not (Fig. 4C). Additional immunizations with all peptides minus the CD4 85A99–118 or CD8 85A145–152 peptides confirm that only an immune response to the CD8 85A99–118 epitope confers protection (Fig. 4C). Mice immunized with peptide pools lacking specific epitopes show antigen specific response identical to those immunized only with the CD4 85A99–118 or CD8 85A145–152 peptides (Fig. 4A and B).

No response to the CD8 85A90–78 epitope is detected in mice immunized with all peptides (p85A Fig. 3) or with peptides covering only this epitope (either as overlapping 15mers or a 9mer). Nor do mice immunized with all peptides without CD8145–152 or all without CD8145–152 and CD4 85A99–118, make a CD8 85A90–78 response. Finally, although we could not induce detectable CD8 85A90–78 responses, we still challenged these animals with Mtb and they show no protection (data not shown).

3.4. Activation status of 85A specific T cells

Because protective local lung immunity is associated with the presence of activated T cells in the lungs [8,9,11], we examined the activation status of antigen specific lung and spleen lymphocytes in immunized mice. Ad85A i.n. induces a higher proportion of effector (CD62L− CD127−) and effector memory (CD62L− CD127+ 85A specific CD8 cells in the lung and spleen compared to p85A i.n. (Fig. 5A and B). Most of the antigen specific lung CD4 cells after i.n. immunization are effector memory phenotype (CD62L− CD44hi), while in the spleen both effector and central memory (CD62L+ CD44lo) cells are seen, irrespective whether Ad85A, r85A or p85A are used for immunization (Fig. 5C and D).

In all cases i.n. administration induces a more activated phenotype of lung and splenic 85A specific cells, compared to the respective parenteral regime (data not shown).

Taken together the results demonstrate that the three delivery platforms and routes of administration induce antigen specific cells with different specificity and activation status.

4. Discussion

We assessed the immunogenicity and protective efficacy of Mtb antigen 85A administered as Ad85A, adjuvanted r85A or adjuvanted p85A and show that all formulations delivered i.n. reduce the lung mycobacterial load, despite the induction of different T cell subsets with differing epitope specificity. For the first time we show that i.n. administration of overlapping synthetic peptides covering the whole sequence of antigen 85A confers protection against Mtb challenge. The data do not establish however, that r85A or p85A are poor parenteral vaccines since it is possible that an improved adjuvant, such as those used by others with recombinant proteins, might improve the protection attained by parenteral immunization [5,20].

In accordance with previous observations in BALB/c mice [19,21], we find that antigen 85A induces responses to three immunodominant epitopes: I-Ed CD499–118, Ld CD870–78 and Kd CD8145–152. Ad85A induces a predominantly CD8T cell response mainly against the CD8 85A90–78 epitope, with minimal but detectable CD8 85A90–78 and CD4 85A99–118 responses. As expected, adjuvanted r85A induces a CD4 response against the dominant I-Ed CD499–118 epitope, while p85A immunization induces both CD4 85A99–118 and CD8 85A145–152 responses. For all regimes the antigen specific cells in the lung are more activated compared to the spleen, with Ad85A inducing the most highly...
activated CD8 cells. These data demonstrate that irrespective of the T cell subset, the presence of highly activated effector/effectort memory antigen specific cells at the site of infection may limit Mtb infection.

Although p85A induces responses to both CD4 85A99–118 and CD8 85A145–152, immunization with the separate peptides allowed us to determine their contribution to Mtb protection and show that only the CD4 response is protective. This may be because while CD4 85A99–118 and CD8 85A70–78 are expressed and can be recognized in Mtb infected cells, CD8 85A145–152 is not expressed. Because responses to all three epitopes are induced by Ad85A (Fig. 3), all three must be expressed in Ad85A infected cells and both the CD8 epitopes can also be detected in transfected P815 cells [22], implying that processing of antigen 85A may be different in Mtb infected macrophages. Such changes in epitope expression in different cells when different vaccine vectors are used, are not unknown; an

---

**Fig. 3.** Specificity of immune responses to antigen 85A. Parenterally or i.n. immunized BALB/c mice were sacrificed 4 weeks after the last immunization and the proportion of lung and spleen CD4 and CD8 lymphocytes producing IFNγ determined by intracellular cytokine staining after 6 h stimulation with the 85A99–118, 85A70–78, and 85A145–152 peptides. (A) Ad85A was administered i.n. or i.m. without adjuvant. (B) r85A was administered i.n. with cholera toxin or s.c. with MPL. (C) p85A were administered i.n. with cholera toxin or s.c. with MPL. Cells from 3 to 4 mice were assayed separately in at least 5 experiments. Error bars show SD.
extreme example is the recent finding of MHC class II restricted epitopes recognized by CD8 T cells in Macaques immunized with a recombinant rhCMV vector [23].

Another example of changed epitope recognition in a mycobacterial antigen after different immunizations has been described previously in C57Bl/6 mice [16]. An adenoviral construct expressing an Ag85B/ESAT6 fusion gene induced a strong CD8 immune response to the ESAT6_{15-29} epitope but no protection. In contrast, immunization with IC31-adjuvanted recombinant protein induced primarily a CD4 response targeted to the Ag85B_{241-255} epitope and efficient protection against Mtb infection. This result too, was ascribed to lack of expression of the ESAT6_{15-29} epitope during Mtb infection.

An alternative explanation might be that because CD8 Ag85B_{145-152} specific cells induced by peptide immunization are less activated than those induced by Ad85A (Fig. 5C and D), they are unable to mediate protection. Furthermore, CD8 Ag85B_{145-152} on its own without CD4 help might induce defective CD8 memory cells [24,25] although clearly Ag85B_{145-152} specific cells efficiently produce IFNγ (and TNF, not shown) in response to antigen (Fig. 3).
A further puzzle in these experiments is why we cannot induce an immune response to the CD8 85A70–78 epitope by peptide immunization, while this is the dominant epitope detected following Ad85A administration and after DNA vaccination [22]. Since CD8 85A70–78 is an LD and CD8 85A145–152 is a Kb epitope [19] it seems unlikely that competition of peptides for MHC class I binding, is the explanation. Furthermore responses to both epitopes are seen in Ad85A immunized (Fig. 3) or DNA immunized mice [22]. Nevertheless, even when CD8 85A145–152 is removed from the peptide immunization mix there is still no response to 85A70–78. It also seems unlikely that the lack of response is due to lack of CD4 help, as we tried immunizing with a mixture of the CD8 85A70–78 and CD4 85A09–118 epitopes.

Interestingly a longer peptide covering the sequence 141–160, in which the CD8 85A145–152 epitope is located, can stimulate cytokine secretion from both CD8 and CD4 cells as shown by others [19] and sporadically in our experiments. The presence of a cryptic CD4 epitope might contribute to the powerful response to the CD8 85A145–152 epitope during peptide immunization. As this region of 85A is recognized by T cells from 90% of Mtb infected humans [2], it may also be among the conserved epitopes, responses to which may benefit Mtb rather than the host [26].

In the light of the recent failure of the parenteral booster vaccine MVA85A to improve protection against tuberculosis over BCG alone, new vaccine strategies are urgently needed [27]. Immunization via the respiratory tract is promising. BCG administered by this route is protective in mice, guinea pigs, cows and primates [10,28–30] and subunit vaccines are protective in mice [4,6] and immunogenic in primates [31]. Peptides with an appropriate adjuvant offer a possible alternative formulation for respiratory administration, with the advantage that immunogenic epitopes can be selected and non-protective ones omitted from the vaccine. However, as shown here, some protective epitopes are not immunogenic when given as peptides. Much further work will be required to identify effective adjuvants that might be used in humans and to investigate the duration of protection after peptide immunization.

5. Conclusions

The three vaccines Ad85A, r85A and p85A are all protective when given i.n. but induce different T cell responses. Responses to the CD4 85A09–118 and CD8 85A70–78, but not the CD8 85A145–152 epitope are protective. Peptide immunization did not induce an immune response to the protective CD8 85A70–78 epitope. These data have important implications for subunit vaccine design and show that the exact specificity of the T cell response to a vaccine antigen may be more important than its magnitude. It remains to be seen whether under other circumstances non-protective CD4 responses may be induced.

Acknowledgement

This study was funded by the UK Medical Research Council, Grant No. G1100085.
References

[1] Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, et al. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 2012;30:2811–23.

[2] Launois P, Deleys R, Nang MN, Drowart A, Andrien M, Dierckx P, et al. T-cell epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infection and Immunity 1994;62:3679–87.

[3] Gonnisetilleke NP, McShane H, Hannan CM, Anderson RJ, Brooksie RH, Hill AV. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette–Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. Journal of Immunology 2003;171:1602–9.

[4] Radosevic K, Wieland CW, Rodrigue A, Weverling GJ, Mintoardjo R, Gillissen G, et al. Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon. Infection and Immunity 2007;75:4105–115.

[5] Lin PL, Dietrich J, Tan E, Abalos BM, Burgos J, Bigbee C, et al. The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection. Journal of Clinical Investigation 2012;122:303–14.

[6] Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, et al. Multi-functional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. Journal of Immunology 2008;181:4955–64.

[7] Wang J, Thorsen I, Stokes RW, Santossouss M, Huygen K, Zganiacz A, et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. Journal of Immunology 2004;173:6357–65.

[8] Lee LN, Ronan EO, de Lara C, Franken KL, Ottenhoff TH, Tchilian EZ, et al. CXCVR is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infection and Immunity 2013;81:3236–7.

[9] Ronan EO, Lee LN, Beverley PC, Tchilian EZ. Immunization of mice with a recombinant adenovirus vaccine inhibits the early growth of Mycobacterium tuberculosis after infection. PLoS ONE 2009;4:e6235.

[10] Tchilian EZ, Ronan EO, de Lara C, Lee LN, Franken KL, Vordermeier MH, et al. Simultaneous immunization against tuberculosis. PLoS ONE 2011;6:e27477.

[11] Jeyanathan M, Mu J, McCormick S, Damjanovic D, Small CL, Shaler CR, et al. Murine airway luminal anti-tuberculosis memory CD8+ T cells by mucosal immunization are maintained via antigen-driven in situ proliferation, independent of peripheral T cell recruitment. American Journal of Respiratory and Critical Medicine 2010;181:862–72.

[12] Copal R, Rangel-Moreno J, Sligh S, Lin Y, Nawar HF, Fallert Juencoa BA, et al. Interleukin-17-dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunology 2013;6:9–13.

[13] Ronan EO, Traynor A, Kavel D, Nunez-Garcia J, Hogarth PJ, Vordermeier HM. Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptional biosignatures in mice. PLoS ONE 2010;5:e11319.

[14] Jeyanathan M, Damjanovic D, Shaler CR, Lai R, Wortzman M, Yin C, et al. Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity. Mucosal Immunology 2012;5(7(November)):103.

[15] Franken KL, Hiemstra HS, van Meijgaard KE, Subronto Y, den Hartigh J, Ottenhoff TH, et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expression and Purification 2000;18:95–9.

[16] Bennekov T, Dietrich J, Rosenkranz I, Stryhn A, Doherty TM, Andersen P. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis. European Journal of Immunology 2006;36:3346–55.

[17] Bileskova R, Elvang TT, Andersen PL, Dietrich J. The HvVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS ONE 2012:e39909.

[18] Zhang H, Hong H, Li D, Ma S, Di Y, Stoten A, et al. Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells. Journal of Biological Chemistry 2009;284:9184–91.

[19] Denis O, Tanghe A, Pafflet K, Jurion F, van den Berg TP, Vanonckelen A, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium tuberculosis H37Rv infection. Infection and Immunity 1998;66:1527–33.

[20] McNeil SE, Rosenkranz J, Agger EM, Andersen P, Perrie Y. Subunit vaccines: dieteroylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. Journal of Pharmaceutical Sciences 2011;100:1856–65.

[21] D’Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, et al. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infection and Immunity 2003;71:483–91.

[22] Baldwin SL, D’Souza CD, Orme IM, Liu MA, Huygen K, Denis O, et al. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tubercle and Lung Disease 1999;79:251–9.

[23] Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors evade CD8+ T cell epitope recognition paradigms. Science 2013;340(6138):e1237874.

[24] Shedlock DJ, Shen H. Requirement for CD4T cell help in generating functional CD8T cell memory. Science 2003;300:337–9.

[25] Sun JC, Bevan MJ. Defective CD8T cell memory following acute infection with out CD4T cell help. Science 2003;339–42.

[26] Comas I, Chakravarti J, Small PM, Galagan J, Niemann K, Kremer K, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyper-conserved. Nature Genetics 2010;42:498–503.

[27] Tamaris MD, Hatheril M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet 2013;381:60117–84.

[28] Cohn ML, Davis CL, Middlebrook C. Airborne immunization against tuberculosis. Science 1958;128:1282–3.

[29] Barclay WR, Busey WM, Dalgard DW, Good RC, Janicki BW, Kasik JE, et al. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette–Guerin. American Review of Respiratory Disease 1973;107:351–8.

[30] Buddle BM, Keen D, Thomson A, Jowett G, McCarthy AR, Heslop J, et al. Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae. Research in Veterinary Science 1995;59:10–6.

[31] Song K, Bolton DL, Wei CJ, Wilson RE, Camp JV, Bao S, et al. Genetic immunization in the lung induces potent local and systemic immune responses. Proceedings of the National Academy of Sciences of the United States of America 2010;107:22123–8.